Valuation: Pacific Software, Inc.

Market Cap 48.82M 42.94M 39.89M 36.69M 68.8M 4.73B 70.04M 477M 186M 2.31B 183M 179M 8B P/E 2019
-2.65x
P/E 2020 -41.2x
Enterprise Value 49.19M 43.26M 40.19M 36.96M 69.32M 4.76B 70.56M 481M 187M 2.32B 185M 181M 8.06B EV / Sales 2019
-
EV / Sales 2020 2,435,972,350x
Free-Float
99%
Yield 2019 *
-
Yield 2020 -
1 day-11.11%
1 week-6.98%
Current month-33.33%
1 month-41.18%
3 months-4.76%
6 months-54.80%
Current year-66.67%
1 week 0.04
Extreme 0.04
0.05
1 month 0.04
Extreme 0.04
0.06
Current year 0.03
Extreme 0.027
0.09
1 year 0.01
Extreme 0.0052
0.12
3 years 0
Extreme 0.001
0.3
5 years 0
Extreme 0.001
2.83
10 years 0
Extreme 0.001
5.59
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2026-06-09
Director TitleAgeSince
Chairman 74 2016-10-21
Change 5-day change 1-year change 3-year change Capi.($)
-11.11%-6.98%+716.33%-21.57% 3.12M
+0.90%-3.38%-3.14%+13.00% 46.35B
+3.13%+5.34%+402.93%+605.08% 40.13B
+2.14%+2.95%+10.83%+65.45% 36.33B
+4.43%-1.51%+6.73%-9.17% 34.6B
+1.23%-2.05%+0.56%+30.76% 26.77B
+0.29%-2.75% - - 16.66B
+14.71%+12.62%+38.50%+146.99% 16.91B
-0.64%-6.52%-0.30%+7.35% 13.05B
+1.82%+0.19%+1.45%-30.74% 13.05B
Average +1.54%+0.42%+130.43%+89.68% 24.38B
Weighted average by Cap. +2.63%+0.23%+76.29%+131.82%

Financials

2019 2020
Net sales - 0.02 0.02 0.02 0.02 0.03 1.94 0.03 0.2 0.08 0.94 0.08 0.07 3.28
Net income -21.11M -18.57M -17.25M -15.86M -29.75M -2.04B -30.28M -206M -80.46M -997M -79.26M -77.54M -3.46B -1.17M -1.03M -959K -882K -1.65M -114M -1.68M -11.47M -4.48M -55.47M -4.41M -4.31M -192M
Net Debt -101K -88.44K -82.16K -75.56K -142K -9.74M -144K -982K -383K -4.75M -378K -369K -16.48M 367K 323K 300K 276K 518K 35.58M 527K 3.59M 1.4M 17.36M 1.38M 1.35M 60.22M
Logo Pacific Software, Inc.
PurMinds Enterprises, Inc., formerly Pacific Software, Inc., is a precision neuro-medicine development company pursuing solutions to neurological and psychiatric disorders. The Company's clinical pipeline includes neuroprotective compounds that restore neuronal functions and can address multiple clinical indications with significant unmet patient needs. The Company is focused on a 4P Medicine platform, in strategic partnership with SpectroChip Global Inc., for early detection and intervention of conditions before irreversible damage occurs. The Company operates under a Health Canada issued Controlled Drugs and Substances License. It has developed a pipeline of proprietary formulations and novel small molecules (NCEs). The Company's pipeline includes PUR100 Series and PUR500 Series.
Employees
2
Date Price Change Volume
26-07-23 US$0.0500 +8.70% 19,300
26-07-22 US$0.0460 -.--% 11,400
26-07-20 US$0.0460 -.--% 150,000
26-07-17 US$0.0460 +6.98% 200,000
  1. Stock Market
  2. Stocks
  3. PFSF Stock